You may be eligible to participate in the BRAVE-EPA Study if you:
Are a VA Eligible Veteran
Do not have a diagnosis of mild cognitive impairment or dementia
Are 50–75 years old
Have or had a parent with Alzheimer’s disease
Are willing to attend study visits in Madison, WI
About the Study:
The purpose of this research study is to evaluate if EPA, an omega-3 fatty acid, improves biomarkers of Alzheimer’s disease, and thinking abilities in middle-aged, cognitively healthy Veterans at risk for this common form of dementia.
The goal of the BRAVE-EPA study is to evaluate if a kind of fish oil called eicosapentaenoic acid (EPA) favorably alters early brain changes associated with Alzheimer’s disease (AD) by improving brain blood flow, spinal fluid markers of AD, and thinking abilities in middle-aged, cognitively-healthy Veterans at risk for this common form of dementia.
What is Involved:
Participants enrolled in the BRAVE-EPA study will visit the William S. Middleton Memorial Veterans Hospital and the University of Wisconsin’s Wisconsin Institutes for Medical Research nine times over the course of 18 months.
Half of the participants in this study will receive a study medication, icosapent ethyl (a purified form of fish oil), and half will receive a “placebo” (an inactive substance designed to mimic the appearance of the study drug). The study drug and placebo capsules will be taken by mouth twice daily. Over the course of the 18-month study you will be asked to undergo:
Questionnaires and detailed thinking tests
Blood draws, physical and neurological exams
Three magnetic resonance imaging (MRI) scans
Three lumbar punctures (LP, also known as spinal taps) for spinal fluid collection
And take 2 pills twice daily of either icosapent ethyl (a purified form of EPA) or placebo medication